Significance of F8 missense mutations with respect to inhibitor formation

Summary

We have identified 1,135 haemophilia A patients with missense mutations associated with mild (46%), moderate (22%), severe (16%), and mixed haemophilia phenotypes (11%). Altogether, we detected 374 different missense mutations of which 195 are not listed in the HAMSTeRS database. While missense mutations are strongly underrepresented within the factor VIII (FVIII) B-domain, they are evenly distributed throughout the entire F8 cDNA sequence. Only 36 (5%) of 720 patients with missense mutations and known inhibitor status showed an association with inhibitor formation. Inhibitor prevalence was four-fold higher for severe haemophilia compared to mild/moderate phenotypes. Mutations associated with inhibitor formation were especially clustered within the C1/C2 domain compared to the other domains (8.7% C1/C2 domain vs. 3.6% non-C1/C2-domain; p-value: 0.01). Three different missense mutations (T314A [T295A], S2010P [S1991P], R2169H [R2150H]) were associated twice with inhibitor formation. Importantly, we found that the risk of inhibitor formation in association with FVIII missense mutations is significant higher if the amino acid substitution belongs to another physicochemical class than the original residue (p-value 0.039). For this purpose distinct classes of substitutions were grouped in association with side chains properties: class I, small/hydrophobic; class II, neutral; class III, acidic; class IV, basic. Thus, although missense mutations were associated with an overall lower risk of inhibitor formation compared to other F8 gene mutation types, different missense mutations correlate with specific risks for inhibitor formation. These differences have to be identified in assigning risk profiles to aid in choice of preventative treatments designed to prevent inhibitor formation.

Keywords

Missense mutations - haemophilia A - inhibitor formation - domains - amino acid classes

• References

• 1 d’Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia 2008; 14 (Suppl. 03) 138-146.
• 2 Ogata K, Selvaraj SR, Miao HZ. et al. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe haemophilia A: implications for genotyping. J Thromb Haemost 2011; 9: 1183-1190.
• 3 Schneppenheim R, Schröder J, Obser T. et al. The problem of novel FVIII missense mutations for haemophilia A genetic counselling. Hämostaseologie 2009; 2: 158-160.
• 4 Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 06) 15-22.
• 5 Taylor WR. The classification of amino acid conservation. J Theor Biol 1986; 119: 205-218.
• 6 Fay PJ. Factor VIII structure and function. Int J Haematol 2006; 83: 103-108.
• 7 Goodeve AC, Rosen S, Verbruggen B. Haemophilia A and von Willebrand disease. Haemophilia 2010; 16 (Suppl. 05) 79-84
• 8 James EA, van Haren, Ettinger RA. et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 2011; 9: 689-699.
• 9 Verbruggen B, Novakova I, Wessels H. et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
• 10 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
• 11 Schwaab R, Oldenburg J, Tuddenham EG. et al. Mutations in hemophilia A. Br J Haematol 1993; 83: 450-458.
• 12 Schwaab R, Oldenburg J, Lalloz MRA. et al. Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Genet 1997; 101: 323-332.
• 13 Oldenburg J, Ivaskevicius V, Rost S. et al. Evaluation of DHPLC in the analysis of hemophilia A. J Biochem Biophys Methods 2001; 47: 39-51.
• 14 Pijnappel WWMP, Kolkman A, Baltissen MPA. et al. Quantitative mass spectrometry of TATA binding protein-containing complexes and subunit phosphorylations during the cell cycle. Proteome Science 2009; 7: 1-11.
• 15 Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hämostaseologie 2010; 4: 207-211.
• 16 Poulsen AL, Pedersen IH, Hvas AM. et al. Assay discrepancy in mild haemophilia: entire population study in a National Haemophilia Centre. Haemophilia 2009; 15: 285-289.
• 17 Bowyer A, Kitchen S, Makris M. The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies. Int Jnl Lab Hem 2010; 33: 154-158.
• 18 Franchini, Montagnana, Targher et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin 2009; 35: 307-312.
• 19 Franchini M, Favaloro EJ, Targher G. et al. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Clin Lab Sci 2012; 49: 137-149.
• 20 Green PM, Bagnall RD, Waseem NH. et al. Haemophilia A mutations in the UK: results of screening one-third of the population. Brit J Haematol 2008; 143: 115-128
• 21 Hay CRM. Ludlam CA Colvin BT et al, on behalf of the UK Haemophilia Centre Directors Organisation. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost 1998; 79: 762-766.
• 22 Eckhardt CL, van Velzen AS, Peters M. et al. for the INSIGHT investigators.. Sevenfold risk for inhibitors in mild/moderate hemophilia with factor VIII missense mutations in two distinct regions. J Thromb Haemost 2011; 9 (Suppl. 02) 300.
• 23 Pavlova A, Delev D, Lacroix-Desmazes S. et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7: 2006-2015.
• 24 Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
• 25 Kurnik K, Bidlingmaier C, Engl W. et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Hemophilia 2010; 16: 256-262.